Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
51 hedge funds and large institutions have $18M invested in Accelerate Diagnostics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 17 closing their positions.
5% more capital invested
Capital invested by funds: $17.2M → $18M (+$803K)
24% less funds holding
Funds holding: 67 → 51 (-16)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
87% less call options, than puts
Call options by funds: $2K | Put options by funds: $15K
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
+$515K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$119K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$16K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell & Co
New York
|
-$778K |
| 2 |
Millennium Management
New York
|
-$356K |
| 3 |
AIC
AWM Investment Company
New York
|
-$281K |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
-$254K |
| 5 |
Morgan Stanley
New York
|
-$167K |
AXDX Hedge Fund Activity: Q2 2023 in Review
51 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2023, worth a combined $18M — up 4.7% from $17.2M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AXDX and 2 opened new positions — a net loss of 15 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Griffin Asset Management, adding an estimated $515K. The largest seller was Cannell & Co, exiting entirely with an estimated $778K sold.
- 51 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2023, down from 67 in Q1 2023.
- Funds reported $18M of Accelerate Diagnostics stock for Q2 2023, up 4.7% quarter-over-quarter.
- 2 funds opened new Accelerate Diagnostics positions in Q2 2023 and 17 closed out, a net change of -15 holders.
- The largest Accelerate Diagnostics buyer in Q2 2023 was Griffin Asset Management, an estimated $515K added.
- The largest Accelerate Diagnostics seller in Q2 2023 was Cannell & Co, an estimated $778K sold.
Based on aggregated 13F filings for Q2 2023.